Back to News
Market Impact: 0.15
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
Source: businesswire.com
Healthcare & Biotech
PureTech announced that Phase 1b results for LYT-200 in relapsed/refractory high-risk myelodysplastic syndromes and acute myeloid leukemia will be presented at ESMO 2026. The announcement provides no efficacy or safety data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
PRTC0.45
More News
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
- Goldman says play defense with these stocks if you're worried about the AI bull failing
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Private Equity Due Diligence: A Buyer Workflow
- Weekly Update: In-App Tutorials, Futures Data, and Watchlist Enhancements